


## YM-298198 hydrochloride

<b>Cat. No.:</b>	HY-103568
<b>CAS No.:</b>	1216398-09-2
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>23</sub> ClN <sub>4</sub> OS
<b>Molecular Weight:</b>	378.92
<b>Target:</b>	mGluR
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	YM-298198 hydrochloride is a high-affinity, selective, orally active, and non-competitive antagonist of metabotropic glutamate receptor type 1 (mGluR1). YM-298198 hydrochloride can be used for the research of neurological disorders <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	mGluR 1									
<b>In Vitro</b>	<p>YM-298198 hydrochloride shows a high affinity for mGluR1 with a K<sub>i</sub> of 19 nM for rat mGluR1-NIH membranes<sup>[1]</sup>.</p> <p>YM-298198 hydrochloride inhibits glutamate-induced inositol phosphate production in mGluR1-NIH3T3 cells, with an IC<sub>50</sub> of 16 nM<sup>[1]</sup>.</p> <p>YM-298198 hydrochloride shows neither agonistic nor antagonistic activity on mGluR2, 3, 4a, 6, or 7b up to 10 μM<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>YM-298198 hydrochloride (30 mg/kg; p.o.) shows a significant analgesic effect in streptozotocin-induced hyperalgesic mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male ICR mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration</td> </tr> <tr> <td>Result:</td> <td>Prolonged nociceptive response latency in streptozotocin (200 mg/kg)-induced hyperalgesic mice.</td> </tr> </table>		Animal Model:	Male ICR mice <sup>[1]</sup>	Dosage:	30 mg/kg	Administration:	Oral administration	Result:	Prolonged nociceptive response latency in streptozotocin (200 mg/kg)-induced hyperalgesic mice.
Animal Model:	Male ICR mice <sup>[1]</sup>									
Dosage:	30 mg/kg									
Administration:	Oral administration									
Result:	Prolonged nociceptive response latency in streptozotocin (200 mg/kg)-induced hyperalgesic mice.									

### REFERENCES

[1]. Kohara, A, et al. Radioligand Binding Properties and Pharmacological Characterization of 6-Amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a High-Affinity, Selective, and Noncompetitive Antagonist of Metabotropic Glutamate Receptor Type 1. *J Pharmacol Exp Ther.* 2005 Oct;315(1):163-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA